NASDAQ OMX

Masergy Webinar Discusses EU General Data Protection Regulation (GDPR) and How it Impacts Business

28.6.2017 11:00 | NASDAQ OMX

Del

1 out of 3 Public Webpages of Leading UK Companies Currently Collect Personal Visitor Information and are Subject to New GDPR Rules

DALLAS, June 28, 2017 (GLOBE NEWSWIRE) -- Masergy today announced its live webinar, titled "Mitigating Business Risks Related to GDPR." The European Union's (EU's) new GDPR rules better protect the privacy and security of EU citizens, but will also deliver a long list of onerous obligations for businesses. Masergy's on-line event provides valuable information to help organizations avoid GDPR pitfalls when preparing for full compliance. Register for the GDPR webinar today: https://maser.gy/gdpr-webinar

The new GDPR rules are applicable to any organization that:

  • Is based in the EU
  • Offers any goods or services to EU citizens
  • Monitors the behavior of EU citizens
  • Holds or processes data on EU citizens

CIOs, CISOs and IT Managers are encouraged to join Peter Wright, Founder and Managing Director at DigitalLawUK and resident GDPR expert, along with Mark Nicholls, Masergy's European Head of Enterprise Security Consulting, as they discuss one of the biggest changes to data protection regulation in nearly 20 years. Specific topics include:

  • The effects that Brexit and GDPR will have on the daily operations of EU businesses.
  • Building a business case to secure budget for GDPR preparation efforts.
  • Recommendations based on real-world analogies and successful deployment examples.

"The threat of non compliance is not merely theoretical," Nicholls stated. "Most leading EU companies collect personal information from website visitors in ways that will violate the GDPR rules when they take effect in May 2018. Unless companies begin their compliance activities now, organizations could be subject to fines as much as 4% of their annual revenue."

About Masergy
Masergy owns and operates the largest independent Software Defined Platform in the world, delivering hybrid networking, managed security and cloud communication solutions to global enterprises. Our patented technology, customizable solutions and unmatched customer experience are why a growing number of leading organizations rely on Masergy to deliver performance beyond expectations. Learn more about Masergy and follow us on our blog Transforming Enterprise IT, Twitter @Masergy, LinkedIn and Facebook.

U.S. Media Contact:
Betsey Rogers for Masergy
BridgeView Marketing
603-821-0809
betsey@bridgeviewmarketing.com

EU Media Contact
Dave Wedderburn
Mantis PR
davewed@mantispr.co.uk




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Masergy Communications Inc via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36Pressemelding

VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850  VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching

Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30Pressemelding

Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.  The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270.  A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company's website beginning approximately two hours after

Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22Pressemelding

Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year27.7.2017 13:00Pressemelding

Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period.   Financial and operating highlights during the first quarter of fiscal 2018 include: Fiscal first quarter worldwide revenue from Impella® heart pumps totaled $127.2 million, an increase of 30% compared to revenue of $97.8 million during the same period of the prior fiscal year.  U.S. revenue from Impella heart pumps grew 28% to $114.7 million and

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00Pressemelding

-   Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia -   TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly

Concurrent Introduces Media Delivery Springboard26.7.2017 17:34Pressemelding

Fully Featured Entry Level Video-on-Demand and Live-Streaming Solutions for Cable Operators ATLANTA, July 26, 2017 (GLOBE NEWSWIRE) -- Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation and delivery of visual assets, introduces today its new Media Delivery Springboard solutions, a cost-effective means for small and medium-sized independent cable operators to ingest, store, transform and deliver video-on-demand (VOD) and live-streaming content.   Traditional content delivery networks come with high start-up costs, which present a challenge for small and mid-size operators that may lack the necessary capital to invest in large-scale infrastructure. Concurrent's new Media Delivery Springboard helps independent cable operators with smaller budgets and limited resources remain competitive with an entry-level video delivery solution requiring minimal infrastructure investment.    There are three options available, including a VOD solution fo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom